Thomas Wilson Eastling
Chief Financial Officer · GYRE THERAPEUTICS, INC.
- 2025
- May 7, 2026
- 3
Summary
Latest filing:
Thomas Wilson Eastling is Chief Financial Officer of GYRE THERAPEUTICS, INC. (GYRE). 3 SEC Form 4 filings on record going back to 2025, most recently on 7 May 2026.
Recent transactions
1The latest SEC Form 4 transaction reported by Thomas Wilson Eastling.
Trading pattern
InsiderAlpha's records for Thomas Wilson Eastling go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Thomas Wilson Eastling files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Thomas Wilson Eastling?
Thomas Wilson Eastling is a corporate insider, tracked as Chief Financial Officer of GYRE THERAPEUTICS, INC. (GYRE). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Thomas Wilson Eastling last file a Form 4?
The most recent primary Form 4 on record is dated 7 May 2026, one of 3 filings going back to 2025.